Milena Gianfrancesco1, Jinoos Yazdany1, Philip C Robinson2,3. 1. Department of Medicine, Division of Rheumatology, University of California, San Francisco, California, USA. 2. University of Queensland Faculty of Medicine. 3. Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Queensland, Australia.
Abstract
PURPOSE OF REVIEW: The novel coronavirus 2019 (COVID-19) pandemic is of special concern for patients with immune-mediated inflammatory disease (IMID) and those who care for them because of the potential for worse outcomes. This article analyzes peer-reviewed research on the epidemiology and outcomes of COVID-19 in those with IMID. RECENT FINDINGS: Published literature on approximately 1400 patients was included from rheumatology, gastroenterology, and dermatology. Data suggest that those who are older and have comorbidities have poorer outcomes. This is consistent with the reports from the general population of patients with COVID-19. Adjusted analyses from the largest published studies demonstrate independent effects of systemic glucocorticoids, as well as age and comorbidities with poorer COVID-19 outcomes (SECURE-IBD registry, n = 525; COVID-19 Global Rheumatology Alliance registry, n = 600); biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe outcomes. These early results will require validation in population-based studies as more data becomes available. SUMMARY: Current data suggest that similar to the general population, age, and comorbidities are risk factors for poorer COVID-19 outcomes in patients with IMID. Additional research is needed to quantify outcomes and risk across rheumatic disease types, comorbidities, and immunosuppressive drugs.
PURPOSE OF REVIEW: The novel coronavirus 2019 (COVID-19) pandemic is of special concern for patients with immune-mediated inflammatory disease (IMID) and those who care for them because of the potential for worse outcomes. This article analyzes peer-reviewed research on the epidemiology and outcomes of COVID-19 in those with IMID. RECENT FINDINGS: Published literature on approximately 1400 patients was included from rheumatology, gastroenterology, and dermatology. Data suggest that those who are older and have comorbidities have poorer outcomes. This is consistent with the reports from the general population of patients with COVID-19. Adjusted analyses from the largest published studies demonstrate independent effects of systemic glucocorticoids, as well as age and comorbidities with poorer COVID-19 outcomes (SECURE-IBD registry, n = 525; COVID-19 Global Rheumatology Alliance registry, n = 600); biologic or targeted synthetic disease-modifying antirheumatic drug therapy has not been associated with more severe outcomes. These early results will require validation in population-based studies as more data becomes available. SUMMARY: Current data suggest that similar to the general population, age, and comorbidities are risk factors for poorer COVID-19 outcomes in patients with IMID. Additional research is needed to quantify outcomes and risk across rheumatic disease types, comorbidities, and immunosuppressive drugs.
Authors: Philip C Robinson; David F L Liew; Jean W Liew; Claudia Monaco; Duncan Richards; Senthuran Shivakumar; Helen L Tanner; Marc Feldmann Journal: Med (N Y) Date: 2020-12-03
Authors: Martin Bergman; Christopher D Saffore; Katherine J Kim; Pankaj A Patel; Vishvas Garg; Si Xuan; Haley B Naik Journal: Adv Ther Date: 2021-09-13 Impact factor: 3.845
Authors: Hannah Bower; Thomas Frisell; Daniela di Giuseppe; Bénédicte Delcoigne; Gerd-Marfie Ahlenius; Eva Baecklund; Katerina Chatzidionysiou; Nils Feltelius; Helena Forsblad-d'Elia; Alf Kastbom; Lars Klareskog; Elisabet Lindqvist; Ulf Lindström; Carl Turesson; Christopher Sjowall; Johan Askling Journal: RMD Open Date: 2021-12
Authors: Joel M Gelfand; April W Armstrong; Stacie Bell; George L Anesi; Andrew Blauvelt; Cassandra Calabrese; Erica D Dommasch; Steve R Feldman; Dafna Gladman; Leon Kircik; Mark Lebwohl; Vincent Lo Re; George Martin; Joseph F Merola; Jose U Scher; Sergio Schwartzman; James R Treat; Abby S Van Voorhees; Christoph T Ellebrecht; Justine Fenner; Anthony Ocon; Maha N Syed; Erica J Weinstein; Jessica Smith; George Gondo; Sue Heydon; Samantha Koons; Christopher T Ritchlin Journal: J Am Acad Dermatol Date: 2020-09-04 Impact factor: 15.487